Ability to acquire drug resistance arises early during the tumorigenesis process

Cancer Research

Volumn 67, Issue 3, 2007, Pages 1130-1137

  Yagüe, Ernesto ^a   Arance, Ana ^a,f   Kubitza, Loïc ^a,g   O'Hare, Michael ^b   Jat, Parmjit ^b,c   Ogilvie, Caroline M ^d   Hart, Ian R ^e   Higgins, Christopher F ^a   Raguz, Selina ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g Mergers and Acquisitions Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; PACLITAXEL; RETINOBLASTOMA PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; VERAPAMIL; VIRUS LARGE T ANTIGEN; VIRUS SMALL T ANTIGEN; XR 9756;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; EMBRYO; EMBRYO CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; MULTIDRUG RESISTANCE; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN VIRUS 40; SKIN FIBROBLAST;

ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL TRANSFORMATION, NEOPLASTIC; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EMBRYO; FIBROBLASTS; GENE EXPRESSION; HUMANS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PRECANCEROUS CONDITIONS; RAS PROTEINS; RETINOBLASTOMA PROTEIN; SKIN; SKIN NEOPLASMS; SKIN PHYSIOLOGY; TELOMERASE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 33847036752     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2574     Document Type: Article

References (42)

1. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
2. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
3. Boehm JS, Hahn WC. Understanding transformation: progress and gaps. Curr Opin Genet Dev 2005;15:13-7.
4. O'Hare MJ, Bond J, Clarke C, et al. Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci U S A 2001;98:646-51.
5. Tarunina M, Alger L, Chu G, Munger K, Gudkov A, Jat PS. Functional genetic screen for genes involved in senescence: role of Tid1, a homologue of the Drosophila tumor suppressor 1(2)tid, in senescence and cell survival. Mol Cell Biol 2004;24:10792-801.
6. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 1997;25:2595-7.
7. Rooney DE, Czepulkowski BH, editors. Human cytogenetics: essential data. Chichester: John Wiley and Sons; 1994.
8. Yague E, Higgins CF, Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther 2004;11:1170-4.
9. Walker J, Martin C, Callaghan R. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 2004;40:594-605.
10. Yague E, Armesilla AL, Harrison G, et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003;278:10344-52.
11. Elliott JI, Raguz S, Higgins CF. Multidrug transporter activity in lymphocytes. Br J Pharmacol 2004;143:899-907.
12. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001;98:31-6.
13. Raguz S, Tamburo De Bella M, Tripuraneni G, et al. Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. Clin Cancer Res 2004;10:2776-83.
14. Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003;3:285-96.
15. MacKenzie KL, Franco S, May C, Sadelain M, Moore MA. Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Exp Cell Res 2000;259:336-50.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
17. Somasundaram K, Zhang H, Zeng YX, et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 1997;389:187-90.
18. Kierstead TD, Tevethia MJ. Association of p53 binding and immortalization of primary C57BL/6 mouse embryo fibroblasts by using simian virus 40 T-antigen mutants bearing internal overlapping deletion mutations. J Virol 1993;67:1817-29.
19. Milyavsky M, Tabach Y, Shats I, et al. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res 2005;65:4530-43.
20. Zimonjic D, Brooks MW, Popescu N, Weinberg RA, Hahn WC. Derivation of human tumor cells in vitro without widespread genomic instability. Cancer Res 2001;61:8838-44.
21. Dimri GP. What has senescence got to do with cancer? Cancer Cell 2005;7:505-12.
22. Helt AM, Galloway DA Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 2003;24:159-69.
23. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
24. Dantzig AH, Law KL, Cao J, Starling JJ. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 2001;8:39-50.
25. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-808.
26. Zhivotovsky B, Orrenius S. Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 2005;331:859-67.
27. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
28. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
29. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347:1593-603.
30. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003;22:7486-95.
31. Slee EA, O'Connor DJ, Lu X. To die or not to die: how does p53 decide? Oncogene 2004;23:2809-18.
32. Gasco M, Crook T. p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist Updat 2003;6:323-8.
33. Clarke AH, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52.
34. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
35. 2/M arrest and apoptosis. Nat Med 1996;2:72-9.
36. Hoffmann J, Schmidt-Peter P, Hansch W, et al. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin Cancer Res 1999;5:2198-204.
37. Nakanishi H, Myoui A, Ochi T, Aozasa K. P-glycoprotein expression in soft-tissue sarcomas. J Cancer Res Clin Oncol 1997;123:352-6.
38. Oda Y, Saito T, Tateishi N, et al. ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer 2005;114:854-62.
39. Ohigashi T, Mizuno R, Nakashima J, Marumo K, Murai M. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 2005;62:61-8.
40. Sato A, Kishida S, Tanaka T, et al. Sall1, a causative gene for Townes-Brocks syndrome, enhances the canonical Wnt signaling by localizing to heterochromatin. Biochem Biophys Res Commun 2004;319:103-13.
41. Yamada T, Takaoka AS, Naishiro Y, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/β-catenin complex in early colorectal carcinogenesis. Cancer Res 2000;60:4761-6.
42. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003;106:758-65.